The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMediumUpdated•Originally published 29 April 2026•Updated 30 April 2026•

1 min read

Strong Q1 Results: Constellium Raises Guidance as Humana Affirms 2026 Outlook

Key Facts

1Constellium reported record quarterly Segment Adjusted EBITDA for Q1 and raised its full-year 2026 guidance.

2Humana reported Q1 pretax results of $1,595 million and affirmed its full-year 2026 adjusted financial guidance.

NYSE-listed firms Constellium and Humana reported robust Q1 2026 results, with Constellium SE posting an adjusted EPS of $1.47 on a 24% year-over-year revenue increase. Following this record performance, CSTM management raised its full-year adjusted EBITDA guidance to a range of $900 million to $940 million. The company is also targeting free cash flow above $275 million for 2026 to accelerate its deleveraging strategy. Meanwhile, Humana reported pretax results of $1,595 million and reaffirmed its adjusted financial outlook for the fiscal year. These specific financial milestones bolster investor confidence in the industrial and healthcare sectors. Analysts remain focused on Constellium's ability to translate high revenue growth into sustained cash flow amid global cost pressures.

about 1 month ago

Version History

Version 1about 1 month ago

What changed: Updated the story to include Constellium's $1.47 adjusted EPS, 24% revenue growth, and specific EBITDA guidance of $900M-$940M.